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Sugar molecules play a vital role on both microbial and mammalian cells, where they are
involved in cellular communication, govern microbial virulence, and modulate host immunity
and inflammatory responses.The complement cascade, as part of a host’s innate immune
system, is a potent weapon against invading bacteria but has to be tightly regulated to pre-
vent inappropriate attack and damage to host tissues. A number of complement regulators,
such as factor H and properdin, interact with sugar molecules, such as glycosaminoglycans
(GAGs) and sialic acid, on host and pathogen membranes and direct the appropriate com-
plement response by either promoting the binding of complement activators or inhibitors.
The binding of these complement regulators to sugar molecules can vary from location to
location, due to their different specificities and because distinct structural and functional
subpopulations of sugars are found in different human organs, such as the brain, kidney,
and eye. This review will cover recent studies that have provided important new insights
into the role of GAGs and sialic acid in complement regulation and how sugar recognition
may be compromised in disease.
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INTRODUCTION
The complement system plays a vital role in the protection of a
host from invading bacteria and other microorganisms. However,
this potent immunological weapon must be tightly regulated, or
there is a risk of attack of host tissues leading to damage via an
inappropriate inflammatory response (1). Sugar molecules pro-
vide a diverse and complex means by which the complement
system can not only identify bacteria and other invading pathogens
as a threat but also identify host surfaces that require protection
(2). With three activating pathways of complement, it is the alter-
native and lectin pathways that utilize sugar molecules the most
(1). The lectin pathway is activated by the recognition of carbo-
hydrate moieties, such as mannose or glucose, on the surface of
bacteria, by the mannose-binding lectin or ficolins (3, 4). On the
other hand, the alternative pathway of complement is modulated
in host tissues by glycans such as sialic acid [the predominant form
being N -acetylneuraminic acid (Neu5Ac)] or the glycosaminogly-
can (GAG) chains of proteoglycans. The presentation of specific
Abbreviations: AMD, age-related macular degeneration; aHUS, atypical hemolytic
uremic syndrome; BM, Bruch’s membrane; CCP, complement control protein; DS,
dermatan sulfate; FH, factor H; FHL-1, factor H-like protein 1; HS, heparan sul-
fate; GAG, glycosaminoglycan; GlcA, glucuronic acid; GlcN, N -glucosamine; IdoA,
iduronic acid; Neu5Ac, N -acetylneuraminic acid.
sialic acid or GAG structures on the surface of a cell, or within
the extracellular matrix, can dictate whether positive or negative
regulation of an immune response occurs, including complement
activation. This is because the sugar compositions of both GAGs
and sialic acid can vary greatly from one organ to another and even
between different regions/microenvironments within the same
tissue (2, 5, 6).
Glycosaminoglycans and sialic acid play an important role in
the recruitment and control of a wide range of innate/cellular
immune system regulatory proteins, as well as proteins involved
in tissue remodeling following an inflammatory response (7, 8).
For example, GAGs are key regulators of pulmonary inflamma-
tion during lung infection through their binding of cytokines,
chemokines, and growth factors,which leads to leukocyte adhesion
and accumulation (9). Interestingly, the protein tumor necrosis
factor-stimulated gene-6, which plays a role in protecting tis-
sues from the damaging effects of inflammation, has recently
been found to antagonize the interaction of the chemokine
CXCL8 with the GAG heparan sulfate (HS) on the surface
of endothelial cells and thereby inhibit neutrophil extravasa-
tion (10). In this mini-review, we will concentrate on the
role of sulfated GAGs (particularly HS) and sialic acid on the
recruitment and regulation of components of the complement
cascade.
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MODULATION OF COMPLEMENT BY SULFATED GAGs
There are four different types of sulfated GAGs that are found
ubiquitously in human tissues – namely chondroitin sulfate, der-
matan sulfate (DS), HS, and keratan sulfate – all of which are
attached to proteoglycan core proteins and have considerable
diversity in their“sequence”of sugars (11). Of these, HS is the most
structurally diverse and plays a vital role in cell differentiation,
signaling, and immune homeostasis (12–16). The HS chain com-
prises repeating disaccharide units of a glucuronic acid (GlcA) or
iduronic acid (IdoA) linked to N -glucosamine (GlcN) (17, 18). As
shown in Figure 1A, each disaccharide has four positions that can
be variably modified with sulfation (or acetylation in the case of
the N position of GlcN) and, along with the epimerization of some
GlcA sugars to IdoA, this allows for immense structural diversity
of HS chains that are typically 50–200 disaccharides in length. This
diversity is made more complex by the subdivision of HS chains
into N -sulfated (NS) regions and N -acetylated (NA) regions (of
variable length) separated by small “transition” (NS/NA) zones
(see Figure 1B). Overall, it is this complexity that provides a
broad range of structures that can be recognized differentially by
proteins, such that the biosynthesis of distinct “sequences” at par-
ticular tissue sites can promote/regulate their binding within a
particular microenvironment (2, 19). For example, the comple-
ment regulatory proteins factor H (FH) and factor H-like protein
1 (FHL-1), a truncated version of FH generated through alterna-
tive splicing [that has 7 rather than 20 complement control protein
FIGURE 1 | Structure of heparan sulfate and the binding of factor H
to human kidney and eye tissue. (A) Schematic showing disaccharide
structures found in the HS chain. These are comprised of glucuronic acid
(GlcA) and N -acetylated glucosamine (GlcNAc), found predominately in
the N -acetylated region, and iduronic acid (IodA) and N -sulfated
glucosamine (GlcNS) that are found in the N -sulfated region. The four
possible sulfation positions are listed as: R1, 6-O-sulfation; R2,
N -sulfation; R3, 2-O-sulfation; and R4, 3-O-sulfation. (B) Diagram
demonstrating the distribution of the N -acetylated and N -sulfated
regions of HS and their separation by short transition regions.
(C) Staining of human kidney glomeruli (top panels) and the macula
region of the human eye (lower panels) for endogenous FH and FH
CCP6–8 and CCP19–20 binding sites; for full details, see Ref. (21).
Endogenous FH (green staining) can be seen in both the Bowman’s
capsule (BC) and glomeruli basement membrane (GBM) in the human
kidney, where this binding is predominately mediated by the CCP19–20
region of the protein. However, the CCP19−20 region of FH binds poorly
to the Bruch’s membrane (BM) of eye, where the interaction of FH is
predominantly mediated by CCP6−8. The Y402H polymorphism, found in
CCP7, alters the binding of FH to BM, demonstrated by the lack of red
staining in the bottom right hand side panel. Scale bars in the top panels
of (C) represent 100µm, and in the lower panels represent 10µm.
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(CCP) repeats], prevent inappropriate alternative pathway activa-
tion/amplification in host tissues; in part, this is mediated by their
binding to HS (and DS) on cell surfaces and within the surround-
ing matrix (20–22). One particular variant of FH/FHL-1 (termed
402H; that has a histidine at residue 402 in CCP7) is associated with
an increased risk of age-related macular degeneration (AMD), a
common cause of blindness in developed nations, and requires a
high level of HS sulfation for its binding (23, 24). Because such
highly sulfated sequences are rare within the human Bruch’s mem-
brane (BM) (an extracellular matrix of the eye), this might be the
underlying cause of why complement dysregulation occurs at this
site; i.e., due to insufficient FH/FHL-1 binding in 402H individuals
(20, 22), leading to local inflammation that drives AMD pathol-
ogy. FHL-1 has been found to be the major form of FH within BM
(22) and unlike FH does not have a second GAG-binding domain
(in CCP19–20) to compensate for its impaired tissue recognition;
FHL-1 also lacks the sialic acid-binding site in CCP20 (see below).
Importantly, the recent finding that the overall amount of HS in
BM falls during normal aging (accompanied by a significant reduc-
tion in the level of sulfation) might explain the age-related nature
of AMD (25); i.e., further impairing binding of the 402H variant
of FH/FHL-1. Age-dependent changes in the sulfation patterns of
HS have also been reported in tissues such as in the aorta (26)
and in outgrowth endothelial cells (27); in the latter, a decrease
in the amount of 6-O-sulfation with age results in a decrease in
the migratory capacity of these cells toward vascular endothelial
growth factor and stromal cell-derived factor 1α.
Properdin has an opposing role to FH/FHL-1 in that it is a
positive regulator of the complement system (28). Properdin sta-
bilizes the alternative pathway C3 convertase (C3bBb) allowing
more conversion of C3 into C3b and thus amplification of com-
plement activation. Because properdin exists as oligomers (dimers,
trimmers, and tetramers), which can bind multiple C3b molecules,
it can therefore act as a platform for the assembly of additional C3
convertases (29, 30). It has also been demonstrated that prop-
erdin can bind to HS and chondroitin sulfate on apoptotic T
cells, thereby aiding their clearance by promoting complement-
mediated opsonization/phagocytosis (31, 32). Furthermore, it has
been shown that properdin and FH bind distinct HS sugars on
renal tubular epithelial cells (33, 34) demonstrating the power of
GAGs to mediate immune homeostasis on tissues by recruiting
both positive and negative regulators of complement through the
presentation of different sulfation patterns [reviewed in Ref. (28)].
MODULATION OF COMPLEMENT BY SIALIC ACID
Sialic acid also mediates complement interactions and this family
of sugars is typically found at the termini of the N - and O-linked
glycans substituting mammalian cell surface and secreted proteins
(35, 36). The basic nine-carbon structure can be modified at the
4, 5, 7, 8, and 9 positions to generate a large amount of structural
diversity (see Figure 2). It is the C2 carbon that forms the gly-
cosidic bond to the neighboring sugar, i.e., at multiple different
positions, allowing for variation in its orientation of presentation
(35, 37, 38). Like GAGs, sialic acids can also control the activa-
tion of complement through binding FH; e.g., on erythrocytes,
conferring protection from the spontaneous tick over of the alter-
native pathway (39). The binding of FH to sialic acid results in an
FIGURE 2 | Structural diversity of sialic acids and their distribution in
the human eye. (A) Schematic of the basic 9 carbon structure of sialic acid
and some of the possible substitutions (35); it is the C2 position that forms
the glycosidic linkage to other saccharides within O- and N -linked glycan
chains. R4, R5, R7, R8, and R9 groups are variably modified with the
chemical groups illustrated. (B) Staining of a tissue section of human
macula with the Maackia amurensis (MAA) lectin was carried out as
described in Bishop et al. (5); MAA has high affinity for sialic acid linked
α2–3 to galactose (Neu5Acα2–3Gal). Staining with MAA is seen throughout
different structures of the eye but with particular intensity on Bruch’s
membrane.
increased affinity for C3b and thus enhances its cofactor and decay
accelerating activities. However, FH binding can be influenced by
the type and modifications of sialic acid, e.g., 9-O-acetylation of
sialic acid reduces the affinity for FH (39, 40). In this regard, the
molecular mechanism by which FH can attach to surfaces via sialic
acid, while simultaneously binding C3b, has recently been eluci-
dated (41); crystal structure analyses identified the amino acid
residues in the CCP20 domain of FH that bind the glycerol side
chain (C7–C9) and carboxyl group of N -acetylneuraminic acid
(Neu5Ac). Furthermore, it was shown that there is a high level
of specificity in the interaction of FH with Neu5Ac since this is
dependent on the type of glycosidic bond present; i.e., FH binds
α2–3, but not α2–6 or α2–8 sialic acid linkages. Mutations in the
residues in FH that are responsible for recognizing sialic acid are
associated with the rare kidney disease atypical hemolytic uremic
syndrome (aHUS) (42). These changes perturb the Neu5Ac bind-
ing pocket and reduce the affinity of FH for sialic acid, providing a
biochemical explanation for poor complement regulation on the
glomerular endothelium in aHUS (41).
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The CCP19–20 region of FH is also known to bind HS (43),
most likely at an interaction surface overlapping that for sialic
acid (41); thus there is the possibility that these sugars might
compete for binding, e.g., on cell/matrix surfaces where both are
present. Although this sialic acid/GAG-binding site in CCP19–
20 does not contribute greatly to FH’s binding to BM (21), it
is known that sialic acid is present throughout the human eye
(5); this includes Neu5Acα2–3 (see Figure 2B). Therefore, it is
possible that sialic acid may contribute to the binding of FH
through other, as of yet uncharacterized, sites. Indeed, treat-
ment of eye tissue with HS/DS-degrading enzymes only reduced
endogenous FH levels by ~50%, consistent with the possibility
that sialic acid could also be mediating binding to structures
including BM (20).
TISSUE SPECIFICITY
As described above, both GAGs and sialic acid display considerable
molecular diversity. However, importantly, there are differences
in the populations of structures/sequences of these sugars found
within different tissues. For example, HS is thought to play a reg-
ulatory role in many physiological processes (13–15) through the
tissue-specific (or least tissue-restricted) biosynthesis of particular
sulfation patterns as a form of “zip code” [reviewed in Ref. (2, 19)].
Its variations in sequence pattern can even be seen between dif-
ferent regions of the same tissue, as illustrated by the distinct HS
epitopes mapped within the human macula (6), within pancreatic
islets (44), and in the human kidney (45).
There is also evidence that functional HS “area codes” are dif-
ferent in the human kidney to those found in the human eye
(21); i.e., those that mediate FH binding. Like BM, the glomerular
basement membrane is an extracellular matrix that protects itself
from complement attack by recruiting FH, in this case, through its
CCP19–20 domain binding (at least in part) to HS (see Figure 1C).
It has been shown previously that, while the CCP19–20 region
mediates the binding of FH to glomeruli, it is the CCP6–8 region
that is mainly responsible for binding to HS (and DS) in BM (20,
21). This demonstrates a level of specificity in the biosynthesis of
functional HS sequences in the different tissues, or alternatively,
that the binding specificity of these two regions of FH has become
tuned to the different “compositions” of HS found in the two
locations. This is also consistent with the observation that muta-
tions in the CCP19–20 region of FH (46, 47), which are mainly
associated with aHUS, do not present with an ocular phenotype
but frequently effect heparin/HS binding [see Ref. (21, 48–50) for
further discussion]. Similarly, the Y402H polymorphism in CCP7
of FH/FHL-1, a major risk factor for AMD, does not predispose
individuals to kidney disease.
Transgenic mouse studies demonstrate that knocking out
expression of FH causes aHUS (51) as well as some features that
resemble AMD (52). Furthermore, by expressing a form of murine
FH without CCPs16–20, it was demonstrated that this region of
FH is important in the development of aHUS (53); this is con-
sistent with the recent findings that the CCP19–20 region of FH
likely plays a critical role in self recognition in kidney glomeruli
through its binding of HS and/or sialic acid (21, 41). In fact, it has
been proposed that FH is held in an inactive “latent” conforma-
tion by intramolecular interactions and upon binding to HS or
sialic acid the conformation changes to one that has higher affin-
ity for C3b and increased co-factor activity (54, 55). Therefore, the
presence of HS or sialic acid on host cells may regulate not only
the localization of FH but also the affinity for C3b.
Infection with enterohemorrhagic E. coli can also cause typical
(or infection-induced) HUS; the shiga toxin produced by the bac-
teria can bind directly to the CCP6–8 or CCP18–20 regions of FH
and impairs cofactor activity on cell surfaces but not in the fluid
phase (56). Thus, it seems likely that surface recognition mediated
by these regions of FH is inhibited through their binding to shiga
toxin, although this requires further investigation. Similarly, the
condition dense deposit disease can be caused by systemic loss of
FH, normally due to mutations affecting the protein structure or
its secretion. The resulting global dysregulation of complement
results initially in progressive nephropathy with dense drusen-like
deposits in the glomerular basement membrane, and later with
drusen formation in BM of the eye (55, 57). However, the Y402H
polymorphism in the HS-binding site of FH is associated with
increased risk of dense deposit disease (58), so a role for GAGs (or
sialic acid) is not an impossibility, but this coding change does also
affect other functional activities of FH [see Ref. (12)].
The exciting work from Blaum and co-workers (41) has demon-
strated that the CCP20 region of FH mediates considerable speci-
ficity for particular sialic acid structures (i.e., for Neu5Acα2–3),
where amino acid residues involved in their recognition are asso-
ciated with complement dysregulation in the kidney (46, 47). This
suggests that there may be parallels with FH’s tissue specificity
for GAG binding (21). In this regard, we know that distinct sialic
acid structures are present in different parts of the eye, including
within BM (5) and, therefore, it will be interesting to see whether
different regions of FH differentially recognize sialic acids in a
tissue-specific manner.
The brain is another organ where interactions of complement
with host sugars have been found to contribute to immune home-
ostasis and become dysregulated in disease; in this context, it is
believed that complement proteins, including FH, are synthesized
locally within brain tissue (59). For example, FH has been shown
to associate with the brain lesions of Alzheimer’s disease patients
through the binding of HS (60), changes in HS structure are asso-
ciated with disease progression (61). HS has been shown to bind
amyloid-β (62) where this is modulated by the level of HS sulfa-
tion (63). In fact, it is believed that neurotoxic amyloid-β competes
with neuroprotective fibroblast growth factor 2 for a common HS
binding site (63). Furthermore, it has been suggested that the pres-
ence of amyloid-β prevents the heparanase-mediated turnover of
HS chains (64), which could lead to enhanced binding of FH to HS
structures within brain lesions, hindering their clearance by com-
plement. HS has also been shown to regulate the processing of the
amyloid precursor protein to amyloid-β by the Alzheimer’s beta-
secretase, BACE-1 (65). This is mediated via direct binding of HS
to this enzyme, where the specificity of the interaction, e.g., with
regard to sulfation pattern, has allowed the generation of heparin
derivatives and HS oligosaccharides with therapeutic potential for
Alzheimer’s disease (66, 67).
The presence of sialic acid on neuronal cells can prevent the
activation of the classical complement pathway by masking the
binding sites for C1q (68). The removal of sialic acid results in
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C1q binding, activation of the classical pathway, and opsonization
of the neuronal cells with C3b; microglial cells in the brain can
then recognize C3b via Complement Receptor 3 (CR3) and acti-
vate the phagocytosis of these labeled cells. It has been postulated
that the presence of sialic acid on the cell surface acts as a marker
of cellular health that may be lost/impaired during inflammation
and oxidative stress (69).
MODULATION OF THE COMPLEMENT RESPONSE BY
PATHOGENS
As described already, FH has two HS-binding regions and at least
one site for interaction with sialic acid and with its flexible, modu-
lar, structure FH is capable of interacting with several self-ligands
on the host surface simultaneously (70), which is believed to
enhance its binding avidity. This allows for the recognition of a
diverse range of cell and tissue types as well as making it harder for
microorganisms to recruit FH to avoid host defense. However, the
interplay between host and pathogen is like a constant weapons
race. It is therefore not surprising that pathogens have evolved
ways to mimic these self-associated molecular patterns (SAMPs)
(71). Many human pathogens, including Pseudomonas aeruginosa
have in common with human cells the sialic acid, Neu5Ac, on their
surface (72), which allows them to recruit FH from the blood and
thereby prevent a complement-mediated response (73). Neisse-
ria gonorrhoeae also have surface sialic acid and this was shown
to bind FH in the CCP16–20 region (74), and in light of recent
discoveries, the sialic acid is likely to bind CCP20 (41). Bacteria
either synthesize the sialic acid de novo or acquire it from their
host by secreting a sialidase enzyme that cleaves sialic acid from
host cells, which can then be taken up and presented via bacter-
ial transporters (75). Currently, no pathogens have developed the
ability to create sulfated GAGs (71, 76). However, bacteria have
developed proteins that mimic host carbohydrates such as Neis-
seria meningitides, which produces a FH-binding protein that has
been shown to bind to the CCP6–8 region of FH (77).
MODULATION OF THE COMPLEMENT RESPONSE BY CANCER
Like pathogens, cancer cells can also protect themselves from
complement-mediated immune activation (78). FH and FHL-1
expression is up-regulated in some cancers (79) and inhibition of
their expression reduces the growth rate of the cells in vivo (80).
Cancer cells also commonly up-regulate sialic acid synthesis (81),
possibly by up-regulating sialyltransferases (78), to reach a state
that has been coined “super-self” (82). It is thought that increased
surface levels of sialic acid confer protection against comple-
ment by recruiting FH (83) – removing sialic acid from cancer
cells enhances their complement-mediated lysis (84) – and con-
tributes to immune evasion from NK and other immune cells by
non-complement-mediated mechanisms (78). Interestingly, many
breast cancer cells have an increased amount of HS proteoglycans
on their surfaces compared to normal mammary cells (85), and
therefore, it is tempting to hypothesize that the up-regulation of
this SAMP, like sialic acid, confers increased protection of cancer
cells to complement by recruiting FH.
CONCLUSION
The structural diversity of GAGs and sialic acids makes a sig-
nificant contribution to the regulation of immune homeostasis
through the formation of “sugar postcodes” in human tissues.
In particular, these sugars represent molecular signals capable of
specifically recruiting either complement inhibitors, or activators,
to a host surface in a tissue-specific fashion. Recent evidence sug-
gests that changes to the GAG/sialic acid“repertoire”in a particular
tissue, whether caused by disease or normal aging, can result in an
inappropriate complement response and tissue damage. In some
circumstances, it may be possible to correct this dysregulation of
the innate immune system; e.g., the use of modified GAGs that
interfere with the binding of properdin (but not FH) to HS on
renal tubular epithelial cells might be of benefit in proteinuric renal
disease (33, 34). As such, drugs aimed at modifying complement–
sugar interactions in a tissue-specific manner could represent a
viable therapeutic option in a number of disease contexts.
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